Every material Form 8-K OmniAb, Inc. has filed with the SEC since July 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
OmniAb reported third-quarter 2026 revenue of $4.0 million, up from $2.2 million a year earlier, and a net loss of $15.7 million, or $0.12 per share, narrowed from $16.5 million, or $0.14 per share. The company raised its full-year 2026 revenue guidance and its year-end cash outlook, which may matter to shareholders because the figures point to higher revenue and a smaller loss than in the prior-year period.
Q3 2026 revenue was $4.0 million versus $2.2 million in Q3 2025; net loss was $15.7 million, or $0.12 per share, versus $16.5 million, or $0.14 per share.
2026 revenue guidance is now $35 million to $39 million, up from $32 million to $36 million previously.
Year-end 2026 cash and cash equivalents outlook is $53 million to $57 million, up from $49 million to $53 million.
In Q3 2026, OmniAb entered a collaboration and license agreement with Eli Lilly and Company eligible for up to $370 million in milestone payments, plus royalties.
OmniAb reported second-quarter 2026 revenue of $13.4 million, up from $3.9 million a year earlier, mainly due to milestone revenue, and its net loss narrowed to $5.9 million from $15.9 million. The company raised its full-year 2026 revenue outlook to $32 million to $36 million from $28 million to $33 million, which indicates management expects higher sales for the year.
Q2 2026 revenue was $13.4 million versus $3.9 million in Q2 2025, driven primarily by milestone revenue.
Q2 2026 net loss was $5.9 million, or $0.05 per share, versus $15.9 million, or $0.15 per share, a year earlier.
2026 revenue guidance raised to $32 million-$36 million from $28 million-$33 million; year-end cash guidance raised to $37 million-$41 million.
Cash, cash equivalents and short-term investments were $52.0 million as of June 30, 2026.
OmniAb, Inc. appointed Amechi Nwachuku as Chief Operating Officer effective July 13, 2026. The filing sets his $445,000 base salary, a 45% target bonus and 800,000 stock options, and describes severance terms, including enhanced change-in-control benefits, which matter to shareholders as they define the compensation cost and potential payouts tied to the new role.
Base salary of $445,000 with an annual target bonus equal to 45% of base salary, prorated for 2026
Stock options to purchase 800,000 common shares granted effective August 1, 2026, vesting over four years
Change-in-control agreement provides severance of one times base salary plus one times maximum target bonus, if terminated without cause or resigning for good reason within 24 months of a change in control
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every OmniAb, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →